



# **Lonza**

Pharma & Biotech

## **Lonza becomes latest One Nucleus partner**

***Cambridge UK: 25 February 2019***

Lonza Biologics becomes the latest One Nucleus Partner. The Partner Program is tailor-made to meet the needs both of the Partner and the interests of OneNucleus members.

Sarah Holland, Global Head of Licensing at Lonza commented 'Lonza has been a member of the OneNucleus ecosystem for a number of years. We are delighted to strengthen our relationship further by becoming a OneNucleus partner. We are committed to supporting innovation and see the building of strong relationships with biotechnology companies and research institutes as a key part of our strategy. We very much look forward to both interacting with new members and building on existing relationships'.

Tony Jones, CEO of One Nucleus expands further 'In order for our sector to collectively deliver better outcomes to patients it is imperative that each part of the ecosystem is connected and performs to the best of its ability. Innovation in the supply chain, driven by such world leaders as Lonza, enables One Nucleus members developing new treatments to develop and manufacture their products in the optimal way. I am delighted Lonza have elected to become a Partner to enable strategic engagement with our members and wider network thereby ensuring their innovation and excellence is accessed whenever appropriate"

ENDS

## About Lonza

Lonza is one of the world's leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. As an integrated solutions provider, Lonza is boosting its value creation along and beyond the healthcare continuum with a strong focus on patient healthcare, consumer preventive healthcare and consumer's healthy environment.

Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life. With the recent Capsugel acquisition, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries.

Benefiting from its regulatory expertise, Lonza is able to transfer its know-how from pharma to hygiene and fast-moving consumer goods all the way to coatings and composites and the preservation and protection of agricultural goods and other natural resources.

Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. The company generated sales of CHF 5.1 billion in 2017 with a CORE EBITDA of CHF 1.3 billion. Further information can be found at [www.lonza.com](http://www.lonza.com).

### Lonza Contact Details

Lonza Pharma & Biotech  
Sanna Fowler, Head Public Relations  
Lonza Pharma & Biotech  
Tel +41 61 316 8929  
[sanna.fowler@lonza.com](mailto:sanna.fowler@lonza.com)

## About One Nucleus

Established in 1997, One Nucleus is the not-for-profit Life Sciences & Healthcare membership organisation centred on the Greater London-Cambridge-East of England corridor. Headquartered in Cambridge, at the heart of Europe's largest Life Sciences & Healthcare cluster, we support those institutions, companies and individuals undertaking activity in or with the above region.

Through providing the local, UK-wide and international connectivity, One Nucleus seeks to enable our members to maximise their performance. This support helping them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D have always been impactful in driving social and economic progress. In an increasingly outsourced, collaborative and multi-disciplinary sector, bringing the best people together is key to translating great innovation into great products that markedly improve patient outcomes and drive economic development. Attracting and enabling the best people to engage with is at the heart of the One Nucleus team ethos and what we continually strive to deliver.

For further information, please contact:

Tony Jones, CEO

Email: [Tony@onenucleus.com](mailto:Tony@onenucleus.com)

Tel: +44 (0)1223 896463

Web: [www.onenucleus.com](http://www.onenucleus.com)